Compare LVWR & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVWR | PALI |
|---|---|---|
| Founded | 2022 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.7M | 359.0M |
| IPO Year | 2022 | 2019 |
| Metric | LVWR | PALI |
|---|---|---|
| Price | $1.61 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 359.8K | ★ 3.1M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.57 | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,672,000.00 | $260,000.00 |
| Revenue This Year | $604.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $0.65 | $1.32 |
| 52 Week High | $6.44 | $2.86 |
| Indicator | LVWR | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 40.09 |
| Support Level | $1.08 | $1.32 |
| Resistance Level | $1.63 | $2.18 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 50.49 | 40.32 |
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.